O objetivo deste estudo foi comparar alterações histológicas induzidas por análogos de prostaglandinas e maleato de timolol na conjuntiva de coelhos. Cinqüenta coelhas da raça Nova Zelândia com idade e peso semelhantes foram divididos em cinco grupos de dez animais. Os olhos esquerdos foram tratados com uma gota diária de bimatoprosta 0,03%, travoprosta 0,004%, latanoprosta 0,005%, maleato de timolol 0,5% ou lágrimas artificiais contendo cloreto de benzalcônio (CBA) durante 30 dias. Os olhos contra-laterais serviram como controles. Realizaram-se biópsias na conjuntiva limbar superior com dimensões de 5 mm x 5 mm no oitavo e trigésimo dias em cinco coelhos de cada grupo. A conjuntiva foi imediatamente fixada com formaldeído a 10% por 24 horas, seguido de coloração por Hematoxilina-Eosina (HE) e Ácido Periódico de Shiff (PAS) e avaliação qualitativa por microscopia óptica. A avaliação histo-morfométrica quantitativa foi realizada usando o programa Image Pro-Plus 4.5. Os parâmetros avaliados foram: infiltrado inflamatório, espessura epitelial, número de células caliciformes, diâmetro e número de vasos sanguíneos. Observou-se leve infiltrado inflamatório focal no tecido conectivo subepitelial nos olhos controle e do grupo CBA, que consistia de aglomerados de linfócitos e raros neutrófilos. Todos os demais grupos exibiram no oitavo e trigésimo dias de tratamento infiltrado inflamatório moderado, composto por linfócitos e neutrófilos, que foi mais denso no grupo tratado com maleato de timolol do que nos grupos dos análogos de prostaglandinas. No trigésimo dia, o grupo que recebeu timolol mostrou aumento da densidade subepitelial de colágeno e aumento estatisticamente significante da espessura epitelial (P=0,004), que não foram observados nos demais grupos. Observou-se um aumento estatisticamente significante do número de vasos no grupo tratado com timolol (P=0,001). O diâmetro vascular no grupo que recebeu travoprosta apresentou aumento estatisticamente significante no oitavo dia de tratamento (P=0,008) e redução no 30º dia (P=0,035). A densidade de células caliciformes aumentou significativamente no grupo que recebeu travoprosta no oitavo dia (P=0,001) e no 30º dia nos grupos tratados com bimatoprosta (P=0,002) e latanoprosta (P=0,009). Conclui-se que, na conjuntiva de coelhos, o número de células caliciformes aumenta com o uso de análogos das prostaglandinas. O estudo sugere que essas drogas, entretanto, induzem menos alterações que o maleato de timolol na conjuntiva de coelhos / The purpose of this study was to compare histological changes induced by prostaglandin analogues and timolol maleate in the rabbit conjunctiva. Fifty New Zealand female rabbits with similar age and weight were divided in five groups of 10 animals. The left eyes were treated with one daily drop of bimatoprost 0,03%, travoprost 0,004%, latanoprost 0,005%, timolol maleate 0,5% or artificial tears containing benzalkonium chloride (BAC) for 30 days. The fellow eyes served as controls. Limbal superior conjunctival biopsies of 5 mm x 5 mm were performed at the 8th and 30th day in five rabbits of each group each time. The conjunctiva was immediately fixed with 10% formaldehyde for 24 hours, followed by Hematoxiline-Eosine (HE) and Periodic Acid Shiff (PAS) staining and optical qualitative microscopic evaluation. Morphohistometric quantitative analyses were conducted using the Image Pro-Plus 4.5 software. The evaluated parameters were: inflammatory infiltrate, epithelial thickness, number of goblet cells, diameter and number of blood vessels. A low level infiltration, consisting of localized clusters of lymphocytes and rare neutrophils, was observed in the subepithelial connective tissue of the control eyes and in the BAC group. At the 8th and 30th day post treatment, all other groups exhibited a diffuse inflammatory infiltrate, composed by lymphocytes and neutrophils, which was denser in the timolol group than in the prostaglandin analogue groups. At the 30th day, the timolol group also showed an increased subepithelial collagen density and a significant increase in epithelial thickness (P=0.004), which was not present in the other groups. A significant increase (P =0.001) in the number of blood vessels was observed in the group treated with timolol. An initial increase in the vascular diameter was observed at the 8th day in the travoprost group (P=0,008) although a significant reduction was observed at the 30th day (P =0,035). The goblet cell density was significantly increased at the 8th day in the group treated with travoprost (P =0.001) and at the 30th day in those treated with bimatoprost (P =0.002) and latanoprost (P =0.009). We conclude that an increase in the number of goblet cell was initially observed with the use of all prostaglandin analogues. This study suggests that these drugs, however, induce fewer changes than timolol maleate in the rabbit conjunctiva

O objetivo deste estudo foi comparar alterações histológicas induzidas por análogos de prostaglandinas e maleato de timolol na conjuntiva de coelhos. Cinqüenta coelhas da raça Nova Zelândia com idade e peso semelhantes foram divididos em cinco grupos de dez animais. Os olhos esquerdos foram tratados com uma gota diária de bimatoprosta 0,03%, travoprosta 0,004%, latanoprosta 0,005%, maleato de timolol 0,5% ou lágrimas artificiais contendo cloreto de benzalcônio (CBA) durante 30 dias. Os olhos contra-laterais serviram como controles. Realizaram-se biópsias na conjuntiva limbar superior com dimensões de 5 mm x 5 mm no oitavo e trigésimo dias em cinco coelhos de cada grupo. A conjuntiva foi imediatamente fixada com formaldeído a 10% por 24 horas, seguido de coloração por Hematoxilina-Eosina (HE) e Ácido Periódico de Shiff (PAS) e avaliação qualitativa por microscopia óptica. A avaliação histo-morfométrica quantitativa foi realizada usando o programa Image Pro-Plus 4.5. Os parâmetros avaliados foram: infiltrado inflamatório, espessura epitelial, número de células caliciformes, diâmetro e número de vasos sanguíneos. Observou-se leve infiltrado inflamatório focal no tecido conectivo subepitelial nos olhos controle e do grupo CBA, que consistia de aglomerados de linfócitos e raros neutrófilos. Todos os demais grupos exibiram no oitavo e trigésimo dias de tratamento infiltrado inflamatório moderado, composto por linfócitos e neutrófilos, que foi mais denso no grupo tratado com maleato de timolol do que nos grupos dos análogos de prostaglandinas. No trigésimo dia, o grupo que recebeu timolol mostrou aumento da densidade subepitelial de colágeno e aumento estatisticamente significante da espessura epitelial (P=0,004), que não foram observados nos demais grupos. Observou-se um aumento estatisticamente significante do número de vasos no grupo tratado com timolol (P=0,001). O diâmetro vascular no grupo que recebeu travoprosta apresentou aumento estatisticamente significante no oitavo dia de tratamento (P=0,008) e redução no 30º dia (P=0,035). A densidade de células caliciformes aumentou significativamente no grupo que recebeu travoprosta no oitavo dia (P=0,001) e no 30º dia nos grupos tratados com bimatoprosta (P=0,002) e latanoprosta (P=0,009). Conclui-se que, na conjuntiva de coelhos, o número de células caliciformes aumenta com o uso de análogos das prostaglandinas. O estudo sugere que essas drogas, entretanto, induzem menos alterações que o maleato de timolol na conjuntiva de coelhos / The purpose of this study was to compare histological changes induced by prostaglandin analogues and timolol maleate in the rabbit conjunctiva. Fifty New Zealand female rabbits with similar age and weight were divided in five groups of 10 animals. The left eyes were treated with one daily drop of bimatoprost 0,03%, travoprost 0,004%, latanoprost 0,005%, timolol maleate 0,5% or artificial tears containing benzalkonium chloride (BAC) for 30 days. The fellow eyes served as controls. Limbal superior conjunctival biopsies of 5 mm x 5 mm were performed at the 8th and 30th day in five rabbits of each group each time. The conjunctiva was immediately fixed with 10% formaldehyde for 24 hours, followed by Hematoxiline-Eosine (HE) and Periodic Acid Shiff (PAS) staining and optical qualitative microscopic evaluation. Morphohistometric quantitative analyses were conducted using the Image Pro-Plus 4.5 software. The evaluated parameters were: inflammatory infiltrate, epithelial thickness, number of goblet cells, diameter and number of blood vessels. A low level infiltration, consisting of localized clusters of lymphocytes and rare neutrophils, was observed in the subepithelial connective tissue of the control eyes and in the BAC group. At the 8th and 30th day post treatment, all other groups exhibited a diffuse inflammatory infiltrate, composed by lymphocytes and neutrophils, which was denser in the timolol group than in the prostaglandin analogue groups. At the 30th day, the timolol group also showed an increased subepithelial collagen density and a significant increase in epithelial thickness (P=0.004), which was not present in the other groups. A significant increase (P =0.001) in the number of blood vessels was observed in the group treated with timolol. An initial increase in the vascular diameter was observed at the 8th day in the travoprost group (P=0,008) although a significant reduction was observed at the 30th day (P =0,035). The goblet cell density was significantly increased at the 8th day in the group treated with travoprost (P =0.001) and at the 30th day in those treated with bimatoprost (P =0.002) and latanoprost (P =0.009). We conclude that an increase in the number of goblet cell was initially observed with the use of all prostaglandin analogues. This study suggests that these drugs, however, induce fewer changes than timolol maleate in the rabbit conjunctiva

Diss. (sammanfattning) Uppsala : Univ., 2003. / Härtill 5 uppsatser.

Development of cataracts is a relatively frequent ocular disease of the dog and cataract extraction via phacoemulsification (PE) is commonly performed by veterinary ophthalmologists. Postoperative ocular hypertension (POH) describes the elevation of pressures within the eye during the acute postoperative period and can result in vision loss and poor surgical outcome. Relatively little is known about risk factors or efficacy of prophylactic treatment for POH, and current clinical practice with regard to pressure monitoring and medication administration are highly variable. The literature on POH prophylaxis in humans indicates that improved efficacy may be achieved with a multi-dose approach and that dorzolamide hydrochloride/timolol maleate (DHTM) may be more efficacious than other pressure lowering medications. The canine literature on POH prophylaxis is limited and DHTM has not yet been evaluated despite common use in the clinical setting. Our objectives, therefore, were to investigate risk factors for POH and to test the hypothesis that perioperative topical ophthalmic dorzolamide hydrochloride 2%/timolol maleate 0.5% (DHTM) reduces the prevalence and/or severity of postoperative ocular hypertension (POH) in dogs undergoing cataract extraction by phacoemulsification (PE). We employed a randomized double-masked placebo-controlled study and enrolled 103 dogs (180 eyes) presenting for unilateral or bilateral PE. Select historical, signalment, ophthalmic examination, and surgical data was collected. Dogs were treated with DHTM or Blink Contacts (BC) placebo at 14- and 2-h preoperatively and at conclusion of surgical closure. Intraocular pressures were assessed by rebound tonometry at 2, 4, 6, and 8 hours after surgery and at 8 am the following morning. POH was defined as IOP>25 mmHg and intervention consisted of latanoprost 0.005% if IOP rose to 26 mmHg - 45 mmHg or surgeon treatment of choice if >45 mmHg. Our investigation of risk factors yielded a statistically significant association only with surgeon and surgical time, which were also associated with one another. DHTM significantly reduced the prevalence of POH in comparison with BC (26% versus 49% of eyes, OR=0.36; 34% versus 62% of dogs, OR=0.32). There was also a trend toward reduction of POH severity in DHTM-treated eyes (POH value 37.17±10.47 mmHg with BC, 32.67±6.39 mmHg with DHTM). DHTM-treated eyes that developed POH were significantly more likely to respond favorably (1 hour post-treatment IOP <25 mmHg) to treatment with latanoprost than those in the BC group (76% versus 51%, OR=3.87). We conclude that multi-dose perioperative administration of DHTM may be recommended in dogs undergoing PE to reduce the risk of POH and improve responsiveness of POH to treatment with latanoprost. / Master of Science

Ralph Schönfelder Untersuchungen zum Einfluss verschiedener Dosierungsintervalle von Dorzolamid, Dorzolamid-Timolol und Latanoprost auf den Intraokulardruck normotensiver Hunde Klinik für Kleintiere, Veterinärmedizinische Fakultät der Universität Leipzig Eingereicht im März 2010 Bibliografische Angaben: 93 S., 27 Abb., 14 Tab., 224 Lit., Anhang mit 2 Abb., 4 Tab. Schlüsselwörter: Glaukom, Intraokulardruck, Prostaglandine, Karboanhydrasehemmer, Timolol, Hund Das Glaukom beim Hund ist ein Notfall, der eine rasche Senkung des erhöhten Intraokulardruckes verlangt, um dem Verlust der Sehfähigkeit und den auftretenden Schmerzen entgegen zu wirken. Die medikamentöse Behandlung ist dabei ein wichtiger Bestandteil. Das Ziel der vorliegenden Arbeit war es, den Effekt der lokal applizierten Wirkstoffe Dorzolamid, Dorzolamid-Timolol und Latanoprost zur Senkung des Intraokulardruckes bei verschiedenen Dosierungsintervallen zu untersuchen. Für jeden Wirkstoff wurden an vier aufeinander folgenden Tagen tonometrische Messungen des Intraokulardruckes mit dem Tonopen-XL als Kontrolle durchgeführt. Anschließend erfolgte eine Verlaufsuntersuchung, in welcher der Einfluss jedes der drei Wirkstoffe auf den Intraokulardruck bei ein- und zweimal täglicher Applikation jeweils vier Tage lang untersucht wurde. Dabei erfolgten Messungen von Intraokularduck, Pupillendurchmesser und konjunktivaler Irritation beider Augen von zehn Hunden (Beagle) jeweils 8.00; 10.00; 12.00; 16.00; 20.00; 22.00; 24.00; 4.00 Uhr. Bei dreimal täglicher Applikation von Dorzolamid und Dorzolamid-Timolol erfolgten zusätzlich 7.00, 15.00 und 23.00 Uhr Tonometrien. Die einmalige Applikation des Wirkstoffes erfolgte 8.00, die zweimalige Applikation 8.00 und 20.00 Uhr sowie 7.00, 15.00 und 23.00 Uhr die dreimalige Applikation. Für jeden Wirkstoff wurde an Tag fünf, nach Beendigung der Applikationen, die Normalisierung des Intraokulardruckes überprüft. Die Ergebnisse wurden nach Applikationshäufigkeit sowie vergleichend analysiert. Dies erfolgte mittels Friedman-Test für drei und mehr k-verbundene Stichproben als Zwei-Weg Varianzanalyse. Ohne Dorzolamidapplikation betrug der Mittelwert des Intraokulardruckes ± SEM am 91 ersten Tag 12,3 ± 0,5 sowie am zweiten, dritten und vierten Tag 12,5 ± 0,4 mmHg, 11,2 ± 0,4 mmHg und 11,0 ± 0,4 mm Hg. Die einmal tägliche Applikation von Dorzolamid führte mit 7,6 ± 0,4 mm Hg am ersten Tag sowie nachfolgend 8,7 ± 0,3 mmHg, 8,6 ± 0,2 sowie 8,3 ± 0,2 mm Hg zu einer signifikanten Drucksenkung. Die zweimalige Applikation von Dorzolamid wies mit 9,6 ± 0,4 mmHg am ersten Tag sowie 7,4 ± 0,4 mmHg, 6,7 ± 0,3 mmHg und 6,6 ± 0,3 mmHg am zweiten, dritten und vierten Tag, das größte Potential zu einer signifikant stärkeren Absenkung des Intraokulardruckes im Vergleich zu Dorzolamid-Timolol und Latanoprost auf. Nach dreimal täglicher Applikation von Dorzolamid trat mit 8,0 ± 0,2 mmHg am ersten Tag und 7,0 ± 0,3 am zweiten sowie 7,6 ± 0,3 mm Hg am dritten und vierten Tag, eine signifikant stärkere, den Intraokulardruck senkende Wirkung im Vergleich zu Dorzolamid-Timolol ein. Ohne Applikation von Dorzolamid-Timolol lag der Mittelwert des IOD ± SEM vom ersten bis vierten Tag bei 10,6 ± 0,4 mmHg, 11,6 ± 0,5 mm Hg, 11,6 ± 0,6 mmHg und 11,2 ± 0,4 mmHg. Bei einmal täglicher Applikation wurden vom ersten bis vierten Tag folgende Werte mit signifikanter Senkung des IOD bestimmt: 7,6 ± 0,4 mmHg, 7,1 ± 0,3 mmHg, 8,6 ± 0,3 mmHg und 9,6 ± 0,3 mmHg. Bei zweimal täglicher Applikation lag der Mittelwert des IOD bei 9,8 ± 0,5 mmHg, am zweiten bis vierten Tag 8,2 ± 0,4 mmHg, 8,6 ± 0,4 mmHg und 7,3 ± 0,2 mmHg. Die dreimalige Applikation führte zu einem Mittelwert des IOD von 8,1 ± 0,3 mmHg am ersten Tag sowie 8,7 ± 0,3 mmHg, 7,8 ± 0,3 mmHg und 7,3 ± 0,3 mmHg am zweiten bis vierten Tag der Studie. Bei der Untersuchung von Latanoprost lag der Mittelwert des IOD ± SEM ohne Applikation bei 9,9 ± 0,3 mmHg am ersten sowie 10,0 ± 0,3 mmHg, 10,0 ± 0,3 mmHg und 9,8 ± 0,2 mmHg am zweiten bis vierten Tag. Bei einmaliger Applikation lag dieser entsprechend bei 9,8 ± 0,3 mmHg, 8,7 ± 0,2 mmHg, 9,0 ± 0,3 und 10,1 ± 0,4 mmHg Nach zweimaliger Applikation betrug er am ersten Tag 9,9 ± 0,3 mmHg, am zweiten bis vierten Tag 9,3 ± 0,4 mmHg, 8,9 ± 0,4 mmHg sowie 8,9 ± 0,3 mmHg. Der Einfluss alller drei Wirkstoffe auf den mittleren Pupillendurchmesser wurde untersucht. Bei einmal- und zweimal-täglicher Applikation von Latanoprost trat mit einer Differenz im Median von 2,5 bzw. 4,7 im Vergleich ohne Applikation eine ausgeprägte Miosis auf. Schließlich wurde die Wirkung auf die Bindehaut durch Ermittlung des Grades der konjunktivalen Irritation bestimmt. Die Applikation von Latanoprost führte dabei zu deutlichen Reizungen der Konjunktiva bis hin zu verstärkter Hyperämie, in einigen Fällen zu konjunktivalem Ödem sowie vereinzelt zu Juckreiz.

INTRODUÇÃO: Fatores angiogênicos têm sido estudados em relação ao seu papel na patogênese do hemangioma da infância (HI). Durante o tratamento com betabloqueador, os pacientes com HI são acompanhados por exame físico e comparações por fotografia e ultrassonografia. Além disso, a dosagem sanguínea e urinária do fator de crescimento do endotélio vascular (VEGF) e a dosagem urinária das metaloproteinases 2 e 9 (MMP-2 e 9) podem ser ferramentas não invasivas para o acompanhamento evolutivo e terapêutico do HI. OBJETIVOS: Estudar os níveis de VEGF plasmático e urinário e MMP- 2 e MMP-9 urinárias em pacientes com HI, com o objetivo de avaliar sua possível relação na angiogênese do HI. MÉTODOS: foram incluídos 68 pacientes com hemangioma infantil e 25 controles, pareados por idade e sexo. Foi instituído tratamento sistêmico com propranolol em 45 crianças e tópico, com timolol, em 23. Os pacientes foram acompanhados por até 12 meses de tratamento com medidas de volume do HI pela ultrassonografia, dosagem plasmática e urinária de VEGF e dosagem urinária de MMP-2 e MMP-9 (ensaio Luminex). RESULTADOS: Os níveis de MMP-2 foram indetectáveis em mais de 50% das amostras. Antes do início do tratamento, não houve diferença dos níveis plasmáticos e urinários de VEGF e urinários de MMP-9 entre os grupos de pacientes com HI e controles. Não foi encontrada diferença significativa nos níveis plasmáticos e urinários dos biomarcadores de acordo com a fase de crescimento do hemangioma (crianças com 12 meses ou menos, em relação às maiores que 12 meses de idade). Não houve correlação entre o tamanho do HI e os níveis dos biomarcadores. Obteve-se correlação positiva significativa entre os níveis urinários de VEGF e MMP-9. No grupo tratado com propranolol, observou-se diminuição significativa do volume do HI com o tratamento, o que não foi verificado no grupo tratado com timolol. A variação dos valores dos biomarcadores obtidas antes, até seis meses e de sete a doze meses de tratamento, mostrou redução significativa de VEGF plasmático e MMP-9 urinária nas crianças tratadas com propranolol. Não foi observada variação significativa dos níveis dos biomarcadores durante o tratamento com timolol. CONCLUSÕES: os níveis plasmáticos e urinários de VEGF e os níveis urinários de MMP-9 não se mostraram bons marcadores de angiogênese aumentada nos pacientes com HI, nem tampouco refletiram o aumento da angiogênese característica da fase proliferativa do HI. No acompanhamento terapêutico dos HIs tratados com propranolol, a medida dos níveis dos biomarcadores mostrou diminuição significativa de VEGF plasmático e MMP-9 urinária, o que não foi observado com o timolol. A redução do volume do HI associada à diminuição dos biomarcadores nos pacientes tratados com propranolol sugeriu que o mecanismo de ação do betabloqueador nos HIs seja também por inibição da angiogênese. Desse modo, as dosagens de VEGF plasmático e MMP-9 urinária podem ser úteis para monitorar a efetividade do tratamento / INTRODUCTION: Angiogenic factors have been studied in regard to their role in the pathogenesis of infantile hemangioma (IH). During ß-blocker treatment, patients were monitored through physical examination and comparisons by photography and ultrasonography. In addition, plasma and urinary levels of vascular endothelial growth factor (VEGF) and urinary levels of matrix metalloproteinases 2 and 9 (MMP-2 and MMP-9) can be non-invasive tools to monitor the evolution of IH and its therapeutic follow-up. OBJECTIVES: To study plasma and urinary levels of VEGF and urinary levels of MMP-2 and MMP-9 in patients with IH, in order to evaluate their potential relation to the IH angiogenesis. METHODS: 68 IH patients and 25 controls were included, matched by age and gender. Systemic treatment with propranolol was administered to 45 patients, while topical timolol was administered to 23 patients. Patients were monitored for up to 12 months of treatment with measurements of IH volume through ultrasonography, plasma and urinary levels of VEGF and urinary levels of MMP-2 and MMP-9 (Luminex assays). RESULTS: MMP-2 levels were not detectable in over 50% of the samples. Before treatment, there was no difference in plasma and urinary levels of VEGF and urinary levels of MMP-9 between IH patients and control group. There was no significant difference in plasma and urinary levels for the biomarkers in accordance to the proliferative phase (12-month-old children or younger, in relation to children over 12 months of age). There was no correlation between IH size and biomarkers levels. There was a significant correlation between urinary levels of VEGF and MMP-9. In the propranolol group, a significant reduction of the IH volume with treatment was observed; this was not observed in the group treated with timolol. The variation of the biomarkers values obtained before, up to six months and from seven to twelve months of treatment indicated significant decrease in plasma levels of VEGF and urinary levels of MMP-9 in children treated with propranolol. It was not observed a significant variation of the biomarkers levels during timolol treatment. CONCLUSIONS: Plasma and urinary levels of VEGF and urinary levels of MMP-9 were not good markers of increased angiogenesis in patients with IH, nor reflected the increase in angiogenesis characteristic of the proliferative phase of IH. During therapeutic monitoring of IH treated with propranolol, a significant decrease in plasma VEGF and urinary MMP-9 levels was observed. The reduction in volume associated to the decrease in biomarkers in patients treated with propranolol suggested that its mechanism of action in IH occurs also through the inhibition of the angiogenesis. Thus, measurements of plasma levels of VEGF and urinary levels of MMP-9 may be useful to monitor the effectiveness of treatment

INTRODUÇÃO: Fatores angiogênicos têm sido estudados em relação ao seu papel na patogênese do hemangioma da infância (HI). Durante o tratamento com betabloqueador, os pacientes com HI são acompanhados por exame físico e comparações por fotografia e ultrassonografia. Além disso, a dosagem sanguínea e urinária do fator de crescimento do endotélio vascular (VEGF) e a dosagem urinária das metaloproteinases 2 e 9 (MMP-2 e 9) podem ser ferramentas não invasivas para o acompanhamento evolutivo e terapêutico do HI. OBJETIVOS: Estudar os níveis de VEGF plasmático e urinário e MMP- 2 e MMP-9 urinárias em pacientes com HI, com o objetivo de avaliar sua possível relação na angiogênese do HI. MÉTODOS: foram incluídos 68 pacientes com hemangioma infantil e 25 controles, pareados por idade e sexo. Foi instituído tratamento sistêmico com propranolol em 45 crianças e tópico, com timolol, em 23. Os pacientes foram acompanhados por até 12 meses de tratamento com medidas de volume do HI pela ultrassonografia, dosagem plasmática e urinária de VEGF e dosagem urinária de MMP-2 e MMP-9 (ensaio Luminex). RESULTADOS: Os níveis de MMP-2 foram indetectáveis em mais de 50% das amostras. Antes do início do tratamento, não houve diferença dos níveis plasmáticos e urinários de VEGF e urinários de MMP-9 entre os grupos de pacientes com HI e controles. Não foi encontrada diferença significativa nos níveis plasmáticos e urinários dos biomarcadores de acordo com a fase de crescimento do hemangioma (crianças com 12 meses ou menos, em relação às maiores que 12 meses de idade). Não houve correlação entre o tamanho do HI e os níveis dos biomarcadores. Obteve-se correlação positiva significativa entre os níveis urinários de VEGF e MMP-9. No grupo tratado com propranolol, observou-se diminuição significativa do volume do HI com o tratamento, o que não foi verificado no grupo tratado com timolol. A variação dos valores dos biomarcadores obtidas antes, até seis meses e de sete a doze meses de tratamento, mostrou redução significativa de VEGF plasmático e MMP-9 urinária nas crianças tratadas com propranolol. Não foi observada variação significativa dos níveis dos biomarcadores durante o tratamento com timolol. CONCLUSÕES: os níveis plasmáticos e urinários de VEGF e os níveis urinários de MMP-9 não se mostraram bons marcadores de angiogênese aumentada nos pacientes com HI, nem tampouco refletiram o aumento da angiogênese característica da fase proliferativa do HI. No acompanhamento terapêutico dos HIs tratados com propranolol, a medida dos níveis dos biomarcadores mostrou diminuição significativa de VEGF plasmático e MMP-9 urinária, o que não foi observado com o timolol. A redução do volume do HI associada à diminuição dos biomarcadores nos pacientes tratados com propranolol sugeriu que o mecanismo de ação do betabloqueador nos HIs seja também por inibição da angiogênese. Desse modo, as dosagens de VEGF plasmático e MMP-9 urinária podem ser úteis para monitorar a efetividade do tratamento / INTRODUCTION: Angiogenic factors have been studied in regard to their role in the pathogenesis of infantile hemangioma (IH). During ß-blocker treatment, patients were monitored through physical examination and comparisons by photography and ultrasonography. In addition, plasma and urinary levels of vascular endothelial growth factor (VEGF) and urinary levels of matrix metalloproteinases 2 and 9 (MMP-2 and MMP-9) can be non-invasive tools to monitor the evolution of IH and its therapeutic follow-up. OBJECTIVES: To study plasma and urinary levels of VEGF and urinary levels of MMP-2 and MMP-9 in patients with IH, in order to evaluate their potential relation to the IH angiogenesis. METHODS: 68 IH patients and 25 controls were included, matched by age and gender. Systemic treatment with propranolol was administered to 45 patients, while topical timolol was administered to 23 patients. Patients were monitored for up to 12 months of treatment with measurements of IH volume through ultrasonography, plasma and urinary levels of VEGF and urinary levels of MMP-2 and MMP-9 (Luminex assays). RESULTS: MMP-2 levels were not detectable in over 50% of the samples. Before treatment, there was no difference in plasma and urinary levels of VEGF and urinary levels of MMP-9 between IH patients and control group. There was no significant difference in plasma and urinary levels for the biomarkers in accordance to the proliferative phase (12-month-old children or younger, in relation to children over 12 months of age). There was no correlation between IH size and biomarkers levels. There was a significant correlation between urinary levels of VEGF and MMP-9. In the propranolol group, a significant reduction of the IH volume with treatment was observed; this was not observed in the group treated with timolol. The variation of the biomarkers values obtained before, up to six months and from seven to twelve months of treatment indicated significant decrease in plasma levels of VEGF and urinary levels of MMP-9 in children treated with propranolol. It was not observed a significant variation of the biomarkers levels during timolol treatment. CONCLUSIONS: Plasma and urinary levels of VEGF and urinary levels of MMP-9 were not good markers of increased angiogenesis in patients with IH, nor reflected the increase in angiogenesis characteristic of the proliferative phase of IH. During therapeutic monitoring of IH treated with propranolol, a significant decrease in plasma VEGF and urinary MMP-9 levels was observed. The reduction in volume associated to the decrease in biomarkers in patients treated with propranolol suggested that its mechanism of action in IH occurs also through the inhibition of the angiogenesis. Thus, measurements of plasma levels of VEGF and urinary levels of MMP-9 may be useful to monitor the effectiveness of treatment

=RESUME= Trois approches différentes ont été comparées pour lestimation de lincertitude de mesure, à savoir celles basées sur des études inter-laboratoire, sur la robustesse et sur la validation. Pour ce faire, deux techniques analytiques séparatives, la chromatographie liquide haute performance (CLHP) et lélectrophorèse capillaire (EC), ont été utilisées pour la détermination de lénantiomère R-timolol dans des échantillons de maléate de S-timolol. Loptimisation de la méthode de CLHP a été effectuée sur une phase chirale à base de cellulose modifiée selon une approche multivariée. En ce qui concerne lEC, une séparation chirale convenable a été obtenue en milieu non aqueux en utilisant de lheptakis(2,3-di-O-méthyl-6-O-sulfo)-β-cyclodextrine comme sélecteur chiral en combinaison avec le camphosulfonate. Les deux méthodes ont été validées pour lusage prédéfini en appliquant la stratégie du profil dexactitude, ce qui a permis également destimer lincertitude de mesure. Par la suite, un test de robustesse a été effectué pour les deux méthodes. Linfluence des paramètres opératoires a été évaluée en considérant non seulement les réponses qualitatives mais surtout les réponses quantitatives. Les résultats de ces dernières (teneurs en R-timolol) ont servi à lestimation de lincertitude de mesure, selon le guide ISO 5725-2. Ce même guide a été utilisé pour évaluer la reproductibilité des résultats obtenus lors des études inter-laboratoire menées avec les deux méthodes. Lincertitude estimée à partir de la reproductibilité, a été trouvée dépendante de la concentration, comme observé également lors des études de validation et de robustesse. Il apparaît que lincertitude obtenue en robustesse prédit très bien celle obtenue en inter-laboratoire et constitue donc une alternative intéressante à cette dernière. Par contre, lincertitude associée à la validation est quant à elle différente de celle des autres approches. Cependant, elle reste parfaitement valable pour autant que le protocole de validation soit en accord avec la routine et que la méthode ne quitte pas le laboratoire qui la validée. Lors de la comparaison des deux méthodes, lincertitude obtenue en CLHP a été trouvée plus faible que celle obtenue en EC. =SUMMARY= Three different approaches (inter-laboratory, robustness and validation) have been applied to the estimation of uncertainty and compared. For that purpose, two analytical separation techniques, namely high performance chromatography liquid (HPLC) and capillary electrophoresis (CE), have been used for the determination of R-timolol enantiomer in S-timolol maleate samples. The optimisation of the HPLC method was carried out on a chiral stationary phase containing modified cellulose, by applying a multivariate approach. Concerning the CE method, a suitable chiral separation was obtained in a nonaqueous medium using heptakis(2,3-di-O-méthyl-6-O-sulfo)-β-cyclodextrin as chiral selector in combination with camphorsulfonate. The two methods were validated for the intended use by applying the strategy of the accuracy profile, which could be used additionally to estimate the uncertainty of measurement. Then, a robustness test was performed for the two methods. The influence of the operating parameters was assessed considering not only the qualitative responses but mainly the quantitative ones (the R-timolol content). The latter were used to estimate the uncertainty of measurement according to the ISO 5725-2 guide. The same guide was applied to evaluate the reproducibility of results obtained in inter-laboratory studies carried out with the two methods. The uncertainty was found to be concentration dependent, as also observed in validation and in robustness studies. The uncertainty obtained by robustness studies predicts well that obtained in inter-laboratory studies and can be proposed as an alternative to the latter. On the other hand, the estimation of uncertainty obtained with the validation studies leads to lower values than those obtained with the two other approaches but is still acceptable as long as the analytical method is used in a single laboratory. When comparing the two analytical methods, the uncertainty obtained in LC was found to be lower than that obtained in CE.

Ralph Schönfelder Untersuchungen zum Einfluss verschiedener Dosierungsintervalle von Dorzolamid, Dorzolamid-Timolol und Latanoprost auf den Intraokulardruck normotensiver Hunde Klinik für Kleintiere, Veterinärmedizinische Fakultät der Universität Leipzig Eingereicht im März 2010 Bibliografische Angaben: 93 S., 27 Abb., 14 Tab., 224 Lit., Anhang mit 2 Abb., 4 Tab. Schlüsselwörter: Glaukom, Intraokulardruck, Prostaglandine, Karboanhydrasehemmer, Timolol, Hund Das Glaukom beim Hund ist ein Notfall, der eine rasche Senkung des erhöhten Intraokulardruckes verlangt, um dem Verlust der Sehfähigkeit und den auftretenden Schmerzen entgegen zu wirken. Die medikamentöse Behandlung ist dabei ein wichtiger Bestandteil. Das Ziel der vorliegenden Arbeit war es, den Effekt der lokal applizierten Wirkstoffe Dorzolamid, Dorzolamid-Timolol und Latanoprost zur Senkung des Intraokulardruckes bei verschiedenen Dosierungsintervallen zu untersuchen. Für jeden Wirkstoff wurden an vier aufeinander folgenden Tagen tonometrische Messungen des Intraokulardruckes mit dem Tonopen-XL als Kontrolle durchgeführt. Anschließend erfolgte eine Verlaufsuntersuchung, in welcher der Einfluss jedes der drei Wirkstoffe auf den Intraokulardruck bei ein- und zweimal täglicher Applikation jeweils vier Tage lang untersucht wurde. Dabei erfolgten Messungen von Intraokularduck, Pupillendurchmesser und konjunktivaler Irritation beider Augen von zehn Hunden (Beagle) jeweils 8.00; 10.00; 12.00; 16.00; 20.00; 22.00; 24.00; 4.00 Uhr. Bei dreimal täglicher Applikation von Dorzolamid und Dorzolamid-Timolol erfolgten zusätzlich 7.00, 15.00 und 23.00 Uhr Tonometrien. Die einmalige Applikation des Wirkstoffes erfolgte 8.00, die zweimalige Applikation 8.00 und 20.00 Uhr sowie 7.00, 15.00 und 23.00 Uhr die dreimalige Applikation. Für jeden Wirkstoff wurde an Tag fünf, nach Beendigung der Applikationen, die Normalisierung des Intraokulardruckes überprüft. Die Ergebnisse wurden nach Applikationshäufigkeit sowie vergleichend analysiert. Dies erfolgte mittels Friedman-Test für drei und mehr k-verbundene Stichproben als Zwei-Weg Varianzanalyse. Ohne Dorzolamidapplikation betrug der Mittelwert des Intraokulardruckes ± SEM am 91 ersten Tag 12,3 ± 0,5 sowie am zweiten, dritten und vierten Tag 12,5 ± 0,4 mmHg, 11,2 ± 0,4 mmHg und 11,0 ± 0,4 mm Hg. Die einmal tägliche Applikation von Dorzolamid führte mit 7,6 ± 0,4 mm Hg am ersten Tag sowie nachfolgend 8,7 ± 0,3 mmHg, 8,6 ± 0,2 sowie 8,3 ± 0,2 mm Hg zu einer signifikanten Drucksenkung. Die zweimalige Applikation von Dorzolamid wies mit 9,6 ± 0,4 mmHg am ersten Tag sowie 7,4 ± 0,4 mmHg, 6,7 ± 0,3 mmHg und 6,6 ± 0,3 mmHg am zweiten, dritten und vierten Tag, das größte Potential zu einer signifikant stärkeren Absenkung des Intraokulardruckes im Vergleich zu Dorzolamid-Timolol und Latanoprost auf. Nach dreimal täglicher Applikation von Dorzolamid trat mit 8,0 ± 0,2 mmHg am ersten Tag und 7,0 ± 0,3 am zweiten sowie 7,6 ± 0,3 mm Hg am dritten und vierten Tag, eine signifikant stärkere, den Intraokulardruck senkende Wirkung im Vergleich zu Dorzolamid-Timolol ein. Ohne Applikation von Dorzolamid-Timolol lag der Mittelwert des IOD ± SEM vom ersten bis vierten Tag bei 10,6 ± 0,4 mmHg, 11,6 ± 0,5 mm Hg, 11,6 ± 0,6 mmHg und 11,2 ± 0,4 mmHg. Bei einmal täglicher Applikation wurden vom ersten bis vierten Tag folgende Werte mit signifikanter Senkung des IOD bestimmt: 7,6 ± 0,4 mmHg, 7,1 ± 0,3 mmHg, 8,6 ± 0,3 mmHg und 9,6 ± 0,3 mmHg. Bei zweimal täglicher Applikation lag der Mittelwert des IOD bei 9,8 ± 0,5 mmHg, am zweiten bis vierten Tag 8,2 ± 0,4 mmHg, 8,6 ± 0,4 mmHg und 7,3 ± 0,2 mmHg. Die dreimalige Applikation führte zu einem Mittelwert des IOD von 8,1 ± 0,3 mmHg am ersten Tag sowie 8,7 ± 0,3 mmHg, 7,8 ± 0,3 mmHg und 7,3 ± 0,3 mmHg am zweiten bis vierten Tag der Studie. Bei der Untersuchung von Latanoprost lag der Mittelwert des IOD ± SEM ohne Applikation bei 9,9 ± 0,3 mmHg am ersten sowie 10,0 ± 0,3 mmHg, 10,0 ± 0,3 mmHg und 9,8 ± 0,2 mmHg am zweiten bis vierten Tag. Bei einmaliger Applikation lag dieser entsprechend bei 9,8 ± 0,3 mmHg, 8,7 ± 0,2 mmHg, 9,0 ± 0,3 und 10,1 ± 0,4 mmHg Nach zweimaliger Applikation betrug er am ersten Tag 9,9 ± 0,3 mmHg, am zweiten bis vierten Tag 9,3 ± 0,4 mmHg, 8,9 ± 0,4 mmHg sowie 8,9 ± 0,3 mmHg. Der Einfluss alller drei Wirkstoffe auf den mittleren Pupillendurchmesser wurde untersucht. Bei einmal- und zweimal-täglicher Applikation von Latanoprost trat mit einer Differenz im Median von 2,5 bzw. 4,7 im Vergleich ohne Applikation eine ausgeprägte Miosis auf. Schließlich wurde die Wirkung auf die Bindehaut durch Ermittlung des Grades der konjunktivalen Irritation bestimmt. Die Applikation von Latanoprost führte dabei zu deutlichen Reizungen der Konjunktiva bis hin zu verstärkter Hyperämie, in einigen Fällen zu konjunktivalem Ödem sowie vereinzelt zu Juckreiz.

Orientador: Vital Paulino Costa / Dissertação (mestrado) - Universidade Estadual de Campinas, Faculdade de Ciências Médicas / Made available in DSpace on 2018-08-24T05:19:20Z (GMT). No. of bitstreams: 1 Santana_AlanaMendonca_M.pdf: 2805390 bytes, checksum: 9512111e988de78a1ffde9d9f877658b (MD5) Previous issue date: 2014 / Resumo: O objetivo deste trabalho foi investigar os efeitos das combinações fixas dos análogos de prostaglandinas com timolol sobre a barreira hematoaquosa, a espessura macular central e a pressão intraocular (PIO), em pacientes pseudofácicos com glaucoma primário de ângulo aberto. Neste ensaio clínico randomizado, com observador mascarado e duração de 6 meses, os pacientes foram tratados uma vez por dia (20:00 horas) com lubrificante (grupo controle) ou com a combinação fixa de maleato de timolol 0,5% e latanoprosta 0,005% (CFLT), maleato de timolol 0,5% e bimatoprosta 0,03% (CFBT) ou maleato de timolol 0,5% e travoprosta 0,004% (CFTT). Foi incluído no estudo apenas um olho de 61 pacientes: CFLT (n=16), CFBT (n=15), CFTT (n=15) e grupo controle (n=15). A barreira hematoaquosa foi avaliada por meio do &quot;laser flare meter¿ antes do início do uso das medicações e após 15 dias, 1,2,3,4,5 e 6 meses de tratamento. A PIO foi medida sempre às 9:00 horas, nas mesmas ocasiões. A espessura macular central foi avaliada por meio da tomografia de coerência óptica antes do uso das medicações, após 1 e 6 meses de tratamento ou na hipótese de piora da acuidade visual. Não houve aumento estatisticamente significante nos valores médios de &quot;flare¿ em comparação aos valores iniciais em todos os grupos (p>0,05) em todas as visitas, exceto no grupo CFTT no primeiro mês (p=0,0476) e no grupo CFLT (p=0,0129) no terceiro mês de seguimento. Não houve diferença estatisticamente significativante entre os valores médios de &quot;flare¿ entre os grupos durante o estudo (p>0,05). A média dos valores da espessura macular central aumentou significativamente nos grupos CFLT (p=0,012) e CFTT (p=0,0419) no primeiro mês de tratamento em relação aos valores iniciais. Não houve aumento estatisticamente significante nos valores médios da espessura macular central em relação aos valores iniciais em todos os grupos após 6 meses de tratamento (p>0,05) e não ocorreu diferença estatisticamente significante entre os grupos durante o estudo (p>0,05). A PIO média inicial foi significativamente menor no grupo controle (p=0,0000). Todas as combinações fixas reduziram significativamente a PIO em todas as visitas (P<0,0001), com efeito hipotensor semelhante entre si (p=0,816). Estes resultados indicam que o uso das combinações fixas de análogos de prostaglandinas com timolol não aumentou significativamente a média dos valores de &quot;flare¿ ou a média da espessura macular após 6 meses de tratamento nesta população / Abstract: The aim of this study was to investigate the effects of prostaglandin analogues and timolol fixed-combinations on the blood-aqueous barrier, central macular thickness and intraocular pressure (IOP) in pseudophakic patients with primary open angle glaucoma. In this randomized, masked-observer, 6-month clinical trial, patients were treated once daily (8 pm) with lubricant eye drops (control group), 0,5% timolol and 0,005% latanoprost fixed-combination (LTFC), 0,5% timolol and 0,03% bimatoprost fixed-combination (BTFC) or 0,5% timolol and 0,004% travoprost fixed-combination (TTFC). One eye of 61 patients were included in the study: LTFC (n=16), BTFC (n=15), TTFC (n=15) and control group (n=15). The blood-aqueous barrier status was assessed using the laser flare meter before the medications were started and after 15 days, 1, 2, 3, 4, 5 and 6 months of treatment. The IOP was measured always at 9 am, at the same intervals. The central macular thickness was evaluated with optical coherence tomography before medications were started, after 1 and 6 months of follow-up or if a patient showed decreased visual acuity at any time during follow-up. There was no significant increase in mean flare measurements from baseline in all groups (p>0.05) in all visits, except TTFC group at 1 month (p=0,0476) and LTFC group at 3 months (p=0,0129). There were no significant differences in mean flare values among the groups (p>0.05). Mean central macular thickness values were significantly higher in LTFC (p=0,012) and TTFC groups (p=0,0419) at 1 month of follow-up. There was no significant increase in mean central macular thickness values from baseline in all groups (p>0.05) after 6 months and no significant differences among the groups (p>0.05) during follow-up. At baseline, mean IOP was significantly lower in control group (p=0,0000). All fixed-combinations significantly reduced IOP in all follow-up visits, with similar lowering effect (p=0,816). These findings indicate that the use of prostaglandin analogues and timolol fixed-combinations didn't significantly increased mean flare values or mean central macular thicknes measurements after 6 months of follow-up in this population / Mestrado / Oftalmologia / Mestra em Ciências Médicas